Company Filing History:
4 out of 5 
3 out of 282 
Years Active: 2019-2024
Title: Yasufumi Murakami: Innovator in Anti-VEGF Antibodies
Introduction
Yasufumi Murakami is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of high-affinity anti-VEGF antibodies. With a total of 4 patents to his name, Murakami's work has the potential to impact therapeutic approaches in treating various diseases.
Latest Patents
Murakami's latest patents include the "High-affinity anti-VEGF antibody KLHa505." This invention aims to provide an antibody with significantly high affinity for vascular endothelial growth factor (VEGF) compared to prior art. The monoclonal antibody binds to VEGF with a dissociation constant of 1×10 mol/L or less. Another patent titled "High-affinity anti-VEGF antibody" shares a similar objective, emphasizing the development of antibodies that can effectively target VEGF.
Career Highlights
Throughout his career, Yasufumi Murakami has worked with various organizations, including Order-Made Medical Research Inc. and Santen Pharmaceutical Co., Ltd. His experience in these companies has allowed him to refine his expertise in antibody development and biotechnology.
Collaborations
Some of Murakami's notable coworkers include Hirotada Akiyama and Shigeki Mukoubata. Their collaborative efforts have contributed to advancements in the field of medical research and antibody development.
Conclusion
Yasufumi Murakami's innovative work in the development of high-affinity anti-VEGF antibodies showcases his commitment to advancing medical science. His contributions are likely to have a lasting impact on therapeutic strategies in the future.